Pharmacogenomics of blood pressure response to antihypertensive treatment.

摘要: UNLABELLED PURPOSE IDENTIFICATION: Inter-individual variability in blood pressure response to treatment is well documented, but a clinically useful means distinguish responders from non-responders has been elusive. With the advent of new technologies and genomic knowledge, more investigators are seeking identify genetic determinants therapy. STUDY SELECTION We identified studies candidate polymorphisms an initial PubMed search using MESH terms 'Hypertension: Drug Therapy' 'Genetics' or 'Pharmacogenetics', limiting results English-language publications on human adults. further specific interest noted earlier reviews performed additional searches based these genes. Pertinent were extracted references already identified. focused clinical trials that measured medication class medications over minimum 4 weeks. DATA EXTRACTION evaluated looking at commonly used classes antihypertensive by major variants. RESULTS OF ANALYSIS: Although many show given varies genotype for different polymorphisms, none genotypes consistently predicted response. CONCLUSIONS Common variants may influence diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, have generally yielded conflicting results. The inclusion pharmacogenomic large other innovative investigative methods provide greater clarity potential role genotyping patients with hypertension.